This column explores how the 340B Drug Pricing Program, despite its intent to support safety net institutions, has unintentionally shifted oncology care to higher-cost hospital settings, impacting efficiency, regulation, and the private...
This column explores how the 340B Drug Pricing Program, despite its intent to support safety net institutions, has unintentionally shifted oncology care to higher-cost hospital settings, impacting efficiency, regulation, and the private...
This column explores how the...